RESUMO
Oxidative stress and inflammation have been considered the main factors in the liver injury of clofibrate (CF). To obtain a novel antihyperlipidemic agent with antioxidant, anti-inflammation and hepatoprotection, the combination of sesamol and clofibric acid moieties was performed and achieved sesamol-clofibrate (CF-Sesamol). CF-Sesamol showed significant hypolipidemia effects in hyperlipidemia mice induced by Triton WR 1339, reducing TG by 38.8% (P < 0.01) and TC by 35.1% (P < 0.01). CF-Sesamol also displayed an alleviating effect on hepatotoxicity. The hepatic weight and hepatic coefficient were decreased. The amelioration of liver function was observed, such as aspartate and lactate transaminases (AST and ALT), alkaline phosphatase (ALP) and total proteins (TP) levels. Liver histopathological examination showed that hepatocyte necrosis, cytoplasmic loosening, nuclear degeneration and inflammatory cell infiltration reduced obviously by treatment with CF-Sesamol. Related molecular mechanisms on hepatoprotection showed that CF-Sesamol up-regulated Nrf2 and HO-1 expression and down-regulated p-NF-κB p65 expression in hepatic tissues. CF-Sesamol has significant antioxidant and anti-inflammatory effects. Plasma antioxidant enzymes such as SOD and CAT increased, anti-lipid peroxidation product MDA decreased. The expression of TNF-α and IL-6 inflammatory cytokines in liver was significantly lower than that in the CF group. The results indicated that CF-Sesamol exerted more potent antihyperlipidemic effects and definite hepatoprotective activity partly through the Nrf2/NF-κB-mediated signaling pathway.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Antioxidantes/farmacologia , Benzodioxóis/farmacologia , Ácido Clofíbrico/farmacologia , Hipolipemiantes/farmacologia , Fenóis/farmacologia , Substâncias Protetoras/farmacologia , Animais , Anti-Inflamatórios não Esteroides/síntese química , Anti-Inflamatórios não Esteroides/química , Antioxidantes/síntese química , Antioxidantes/química , Benzodioxóis/sangue , Benzodioxóis/química , Ácido Clofíbrico/sangue , Ácido Clofíbrico/química , Relação Dose-Resposta a Droga , Hiperlipidemias/induzido quimicamente , Hiperlipidemias/tratamento farmacológico , Hipolipemiantes/síntese química , Hipolipemiantes/química , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Camundongos , Camundongos Endogâmicos , Simulação de Acoplamento Molecular , Estrutura Molecular , Estresse Oxidativo/efeitos dos fármacos , Fenóis/sangue , Fenóis/química , Polietilenoglicóis , Substâncias Protetoras/síntese química , Substâncias Protetoras/química , Relação Estrutura-AtividadeRESUMO
Two studies to examine the effect of waterborne clofibric acid (CA) on growth-rate and condition of rainbow trout were conducted using accepted regulatory tests (Organisation for Economic Co-operation and Development [OECD] 215). The first study (in 2005) showed significant reductions after 21 d of exposure (21-d growth lowest-observed-effect concentration [LOEC] = 0.1 µg/L, 21-d condition LOEC = 0.1 µg/L) that continued to 28 d. Growth rate was reduced by approximately 50% (from 5.27 to 2.67% per day), while the condition of the fish reduced in a concentration-dependant manner. Additionally, in a concentration-dependent manner, significant changes in relative liver size were observed, such that increasing concentrations of CA resulted in smaller livers after 28-d exposure. A no-observed-effect concentration (NOEC) was not achieved in the 2005 study. An expanded second study (in 2006) that included a robust bridge to the 2005 study, with four replicate tanks of eight individual fish per concentration, did not repeat the 2005 findings. In the 2006 study, no significant effect on growth rate, condition, or liver biometry was observed after 21 or 28 d (28-d growth NOEC = 10 µg/L, 28-d condition NOEC = 10 µg/L), contrary to the 2005 findings. We do not dismiss either of these findings and suggest both are relevant and stand for comparison. However, the larger 2006 study carries more statistical power and multiple-tank replication, so probably produced the more robust findings. Despite sufficient statistical power in each study, interpretation of these and similar studies should be conducted with caution, because much significance is placed on the role of limited numbers of individual and tank replicates and the influence of control animals.
Assuntos
Ácido Clofíbrico/toxicidade , Oncorhynchus mykiss/crescimento & desenvolvimento , Testes de Toxicidade Crônica/métodos , Poluentes Químicos da Água/toxicidade , Animais , Anticolesterolemiantes/sangue , Anticolesterolemiantes/toxicidade , Composição Corporal/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Ácido Clofíbrico/sangue , Relação Dose-Resposta a Droga , Feminino , Oncorhynchus mykiss/sangue , Tamanho do Órgão/efeitos dos fármacos , Poluentes Químicos da Água/sangueRESUMO
Perfluorooctanesulfonamides, such as N-ethyl perfluorooctanesulfonamidoethanol (N-EtFOSE), are large scale industrial chemicals but their disposition and toxicity are poorly understood despite significant human exposure. The hypothesis that subacute exposure to N-EtFOSE, a weak peroxisome proliferator, causes a redox imbalance in vivo was tested using the known peroxisome proliferator, ciprofibrate, as a positive control. Female Sprague-Dawley rats were treated orally with N-EtFOSE, ciprofibrate or corn oil (vehicle) for 21 days, and levels of N-EtFOSE and its metabolites as well as markers of peroxisome proliferation and oxidative stress were assessed in serum, liver and/or uterus. The N-EtFOSE metabolite profile in liver and serum was in good agreement with reported in vitro biotransformation pathways in rats and the metabolite levels decreasing in the order perfluorooctanesulfonate >> perfluorooctanesulfonamide ~ N-ethyl perfluorooctanesulfonamidoacetate >> perfluorooctanesulfonamidoethanol approximately N-EtFOSE. Although N-EtFOSE treatment significantly decreased the growth rate, increased relative liver weight and activity of superoxide dismutases (SOD) in liver and uterus (total SOD, CuZnSOD and MnSOD), a metabolic study revealed no differences in the metabolome in serum from N-EtFOSE-treated and control animals. Ciprofibrate treatment increased liver weight and peroxisomal acyl Co-A oxidase activity in the liver and altered antioxidant enzyme activities in the uterus and liver. According to NMR metabolomic studies, ciprofibrate treated animals had altered serum lipid profiles compared to N-EtFOSE-treated and control animals, whereas putative markers of peroxisome proliferation in serum were not affected. Overall, this study demonstrates the biotransformation of N-EtFOSE to PFOS in rats that is accompanied by N-EtFOSE-induced alterations in antioxidant enzyme activity.
Assuntos
Ácidos Alcanossulfônicos/metabolismo , Poluentes Ambientais/toxicidade , Fluorocarbonos/metabolismo , Hidrocarbonetos Fluorados/toxicidade , Sulfonamidas/toxicidade , Superóxido Dismutase/metabolismo , Acil-CoA Oxidase , Ácidos Alcanossulfônicos/química , Animais , Biomarcadores/metabolismo , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/sangue , Poluentes Ambientais/sangue , Poluentes Ambientais/química , Feminino , Ácidos Fíbricos , Fluorocarbonos/química , Hidrocarbonetos Fluorados/sangue , Hidrocarbonetos Fluorados/química , Fígado/metabolismo , Oxirredutases/metabolismo , Ratos , Ratos Sprague-Dawley , Sulfonamidas/sangue , Sulfonamidas/química , Superóxido Dismutase/efeitos dos fármacos , Testes de Toxicidade , Útero/metabolismoRESUMO
Etofibrate, fenofibrate, and atorvastatin were determined in their pharmaceutical preparations and human plasma using differential pulse polarographic and square wave voltammetric techniques by reduction at a dropping-mercury working electrode versus Ag/AgCl reference electrode. The reversibility of the electrode reactions was tested using cyclic voltammetry, and they were found to be irreversible reduction reactions. Optimum conditions such as pH, scan rate, and pulse amplitude were studied, and validation of the proposed methods was performed. The proposed methods proved to be accurate, precise, robust, and specific for determination of the 3 drugs. The relative standard deviation values were <2%, indicating that these methods are precise. Limits of detection and quantitation were in the ranges of 0.037-0.21 and 0.12-0.71 microg/mL, respectively, indicating high sensitivity.
Assuntos
Anticolesterolemiantes/análise , Ácido Clofíbrico/análogos & derivados , Fenofibrato/análise , Ácidos Heptanoicos/análise , Hipolipemiantes/análise , Pirróis/análise , Anticolesterolemiantes/sangue , Atorvastatina , Ácido Clofíbrico/análise , Ácido Clofíbrico/sangue , Eletroquímica , Fenofibrato/sangue , Ácidos Heptanoicos/sangue , Humanos , Concentração de Íons de Hidrogênio , Hipolipemiantes/sangue , Indicadores e Reagentes , Polarografia , Pirróis/sangue , Padrões de Referência , Reprodutibilidade dos Testes , SoluçõesRESUMO
The lipid-lowering drug ciprofibrate stimulates gastrin-producing cells in the rat stomach without lowering gastric acidity. Although suggested to be a luminal action on antral peroxisome proliferator-activated receptor-alpha (PPAR-alpha), the mechanism is still not fully elucidated. Gastric bypass was surgically prepared in male Sprague-Dawley rats. Gastric-bypassed and sham-operated rats were either given ciprofibrate (50 mg.kg(-1).day(-1) in methocel) or vehicle alone for 7 wk. PPAR-alpha knockout (KO) and wild-type (WT) mice were either given ciprofibrate (500 mg.kg(-1).day(-1) in methocel) or vehicle alone for 2 wk. The concentration of gastrin in blood was analyzed. Antral G cell density and gastrin mRNA abundance were determined by using immunostaining and Northern blot analysis. Ciprofibrate did not raise plasma gastrin or G cell density in gastric-bypassed rats, although the gastrin mRNA level was slightly increased. In contrast, ciprofibrate induced hypergastrinemia, a 50% increase in G cell density, and a threefold increase in gastrin mRNA in sham-operated rats. In PPAR-alpha KO mice, ciprofibrate did not raise G cell density or the gastrin mRNA level. The serum gastrin level was reduced by ciprofibrate. In WT mice, ciprofibrate induced hypergastrinemia, a doubling of G cell density, and a threefold increase in gastrin mRNA. Comparing animals dosed with vehicle only, PPAR-alpha KO mice had higher serum gastrin concentration than WT mice. We conclude that the main effects of ciprofibrate on G cells are mediated from the antrum lumen, and the mechanism is dependent on PPAR-alpha. The results indicate that PPAR-alpha may have a role in the physiological regulation of gastrin release.
Assuntos
Ácido Clofíbrico/análogos & derivados , Células Secretoras de Gastrina/efeitos dos fármacos , Gastrinas/metabolismo , PPAR alfa/fisiologia , Antro Pilórico/efeitos dos fármacos , Animais , Ácido Clofíbrico/sangue , Ácido Clofíbrico/farmacologia , Feminino , Ácidos Fíbricos , Derivação Gástrica , Fígado/anatomia & histologia , Fígado/efeitos dos fármacos , Masculino , Camundongos , Camundongos Knockout , Tamanho do Órgão , PPAR alfa/agonistas , PPAR alfa/deficiência , Antro Pilórico/fisiologia , Ratos , Ratos Sprague-Dawley , Somatostatina/biossínteseRESUMO
A selective high-performance liquid chromatographic method to assess either bezafibrate, ciprofibrate or fenofibric acid plasma levels is described. Drugs are extracted with diethyl ether, after acidification with HCL. An isocratic acetonitrile 0.02 M H3PO4 (55:45) mobile phase, a C18 microns) column and UV detection are used. The LOQ found was 0.25 microgram/ml for the three fibrates. Intra- and inter-assay accuracy ranges were 90-107% and 82-111%: 96-115% and 94-107%: 94-114% and 94-126% for bezafibrate, ciprofibrate and fenofibric acid, respectively. Intra- and inter-assay precision (C.V.% ranges) were 1.72-3.06% and 2.66-7.67%: 1.88-4.64% and 0.62-2.99%: 1.26-4.69% and 3.56-7.17% for the three fibrates studied. Its sensitivity, accuracy and precision make it a useful tool for monitoring plasma levels of these drugs in a clinical setting and for research purposes.
Assuntos
Bezafibrato/sangue , Cromatografia Líquida de Alta Pressão/métodos , Ácido Clofíbrico/análogos & derivados , Fenofibrato/análogos & derivados , Hipolipemiantes/sangue , Calibragem , Ácido Clofíbrico/sangue , Fenofibrato/sangue , Ácidos Fíbricos , Humanos , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
The aim of this study was to establish whether the individual enantiomers of racemic ciprofibrate, a potent hypolipidaemic agent and peroxisome proliferator, differ significantly in either pharmacological potency or toxic potential. After a single oral dose to male Fischer F344 rats at dosages below 10 mg/kg, S(-) ciprofibrate produced slightly, but statistically significantly, greater reductions in plasma concentrations of cholesterol than R(+) ciprofibrate. Similarly, at low concentrations in F344 rat hepatocyte cultures, S(-) ciprofibrate produced slightly, but statistically significantly, greater inductions of peroxisomal beta-oxidation activity than R(+) ciprofibrate. However, after seven daily doses, the differences in pharmacological effects of the two enantiomers were no longer apparent. Furthermore, in contrast to its effects in vitro, R(+) ciprofibrate produced slightly, but statistically significantly, greater inductions of peroxisomal beta-oxidation activity in vivo than S(-) ciprofibrate. These observations may be possibly explained on the basis that following multiple dosing, plasma concentrations of R(+) ciprofibrate 24 hr post-dose were greater than those of its optical antipode. Thus the slightly greater potency of the S(-) enantiomer after a single dose may have been overcome by the greater plasma concentrations of the less potent enantiomer. Both enantiomers produced similar reductions in plasma concentrations of thyroxine. The data indicate that at low dosages S(-) ciprofibrate is a slightly more potent hypolipidaemic agent after a single dose in rats and a slightly more potent peroxisome proliferator at low concentrations in vitro. However, following multiple dosing, both enantiomers produced changes in plasma concentrations of lipids, hepatic enzyme activities and plasma concentrations of thyroxine which were of comparable magnitude to those produced by the racemate. Since these early changes have been linked mechanistically to the chronic toxicity of the racemate in the rat, it could be predicted that the individual enantiomers of ciprofibrate under conditions employed in chronic safety studies, would produce the same spectrum of rodent toxicity as the racemate.
Assuntos
Colesterol/sangue , Ácido Clofíbrico/análogos & derivados , Fígado/efeitos dos fármacos , Animais , Ácido Clofíbrico/sangue , Ácido Clofíbrico/farmacologia , Relação Dose-Resposta a Droga , Regulação para Baixo , Ácidos Fíbricos , Masculino , Ratos , Ratos Endogâmicos F344 , Estereoisomerismo , Fatores de Tempo , Triglicerídeos/sangueRESUMO
A rapid, sensitive, and selective HPLC assay was developed for the simultaneous determination of ethyl clofibrate and its major metabolite, clofibric acid, in plasma of humans and rats. The assay involves extraction of the compounds into chloroform-isoamyl alcohol (99:1, v/v) from plasma acidified with sulfuric acid. For human plasma, the overall recoveries of ethyl clofibrate and clofibric acid were 63 and 90%, respectively. The limits of detection of the assay for ethyl clofibrate and clofibric acid in human plasma were 1.1 and 1.5 micrograms/ml, respectively. Limits of quantitation of the assay for ethyl clofibrate and clofibric acid in human plasma were 3.6 and 4.9 micrograms/ml, respectively. The HPLC assay was used to monitor the plasma concentration-time profiles of ethyl clofibrate released from polylactic nanocapsules both in man and rat. The simultaneous determination of ethyl clofibrate and clofibric acid provided evidence that these colloidal systems are stable in human plasma whereas they are lysed in rat plasma.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Clofibrato/sangue , Ácido Clofíbrico/sangue , Animais , Cápsulas , Humanos , Ratos , Ratos Wistar , Espectrofotometria UltravioletaRESUMO
rac-2 described as a metabolite of rac-1 was synthesized in four steps starting with rac-3. Partial dehalogenation occurs with LiAlH4. A new structure assignment of the resulting stereoisomers resulted from NMR spectroscopy. After oral administration of rac-1 in multiple dose studies to volunteers, rac-2 could not be detected within the limitations of sensitivity of HPLC (UV-detector) in plasma or in urine.
Assuntos
Ácido Clofíbrico/análogos & derivados , Hipolipemiantes/farmacocinética , Adulto , Biotransformação , Cromatografia Líquida de Alta Pressão , Ácido Clofíbrico/sangue , Ácido Clofíbrico/farmacocinética , Ácido Clofíbrico/urina , Ácidos Fíbricos , Humanos , Hipolipemiantes/sangue , Hipolipemiantes/urina , Masculino , Espectrofotometria UltravioletaRESUMO
Clofibryl and fenofibryl acyl (ester) glucuronides (CAG and FAG) are major metabolites in humans of the hypolipidaemic drugs clofibrate and fenofibrate, respectively. We have investigated three inter-related aspects of the reactivity of CAG and FAG in human serum albumin (HSA) solution, human plasma and in buffer at pH 7.0: namely (a) rearrangement via acyl migration to glucuronic acid esters of clofibric acid (CA) and fenofibric acid (FA), (b) hydrolysis of the parent glucuronide and rearrangement products to yield CA and FA and (c) the formation of covalent adducts with albumin and plasma protein. CAG was more reactive than FAG in all media, especially the protein solutions. The reactivity of both glucuronides was accelerated in protein solution compared with buffer and this was more marked in plasma than in HSA solution. The predominant reaction during the initial stages of the incubation was formation of isomeric rearrangement products. In the protein solutions, CA and FA were the major reaction products after 24 hr, compared to the rearranged isomers in buffer. Protein binding of 14C to HSA was markedly higher after incubation of CAG and FAG labelled on the glucuronyl moiety compared with the label on the aglycone. This is consistent with the covalent binding of CAG and FAG to protein proceeding via the formation of a Schiff's base rather than by transacylation.
Assuntos
Ácido Clofíbrico/química , Fenofibrato/análogos & derivados , Glucuronatos/química , Soluções Tampão , Ácido Clofíbrico/sangue , Fenofibrato/sangue , Fenofibrato/química , Glucuronatos/sangue , Humanos , Técnicas In Vitro , Ligação Proteica , Albumina Sérica/química , SoluçõesRESUMO
Genetically obese Zucker (fa/fa) rats were used as an experimental model to study the effects of hypolipidemic agents on peroxisome proliferation; comparison was made with Zucker lean phenotype (Fa/-) and Sprague-Dawley strain/phenotype. The pharmacokinetics of a single administration of ciprofibrate (1 or 3 mg/kg), appeared to be similar in all strains/phenotypes. After a 2-week oral administration at the same dosages, there were dosage-related increases in hepatocellular peroxisomal yield and in the hepatic enzymes' cyanide-insensitive acyl-CoA oxidase and catalase. The peroxisomal yield was less increased in Zucker than in Sprague-Dawley rats, while the enzyme activities were similarly increased. Although the absolute specific activity of microsomal omega-lauryl hydroxylase (cytochrome P4504A1) was lower in Zucker rats, it was increased more in this strain than in Sprague-Dawley rats in response to drug exposure. The hypolipidemic effect (cholesterol and triglyceride reduction) was more pronounced in Zucker obese rats. Based on biochemical and morphological results, no major differences between strains/phenotypes in terms of peroxisome proliferation were observed following a 2-week administration of ciprofibrate.
Assuntos
Ácido Clofíbrico/análogos & derivados , Hipolipemiantes/farmacologia , Fígado/efeitos dos fármacos , Microcorpos/efeitos dos fármacos , Obesidade/genética , Animais , Colesterol/sangue , Ácido Clofíbrico/sangue , Ácido Clofíbrico/farmacocinética , Ácido Clofíbrico/farmacologia , Sistema Enzimático do Citocromo P-450/biossíntese , Sistema Enzimático do Citocromo P-450/efeitos dos fármacos , Indução Enzimática/efeitos dos fármacos , Ácidos Fíbricos , Isoenzimas/biossíntese , Isoenzimas/efeitos dos fármacos , Fígado/enzimologia , Fígado/ultraestrutura , Masculino , Microcorpos/química , Microcorpos/metabolismo , Ratos , Ratos Sprague-Dawley , Ratos Zucker , Valores de Referência , Especificidade da Espécie , Triglicerídeos/sangueRESUMO
Recent studies have shown that acyl-glucuronide conjugates are chemically reactive electrophilic metabolites that can undergo transacylation reactions resulting in intra-molecular rearrangement, hydrolysis and covalent binding of aglycone to albumin both in vitro and in vivo. The hypolipidaemic agent clofibrate is eliminated almost entirely as clofibric acid glucuronide in humans and rats. The formation of clofibric acid-protein adducts was investigated in 14 patients receiving 0.5-2.0 g/day of clofibrate for hypercholesterolaemia, and in liver homogenates from 20 rats administered 280 mg/kg/day of clofibric acid for up to 21 days. Total clofibric acid concentrations in the patients ranged from 0 to 114 mg/L. Covalently bound clofibric acid-protein adducts were detected in all patients, even in one subject in whom there was no measurable plasma clofibric acid. Concentrations ranged from 2.2 to 53.4 ng/mg protein and, in eight patients receiving 1.0 g/day of clofibrate, were correlated (P less than 0.05) with renal function as assessed by creatinine clearance. Clofibric acid-protein adducts were also present in rat liver homogenates, and increased with increasing duration of treatment (P less than 0.0001), from a mean (SE) of 10.1 (0.7) to 32.3 (1.6) ng/mg protein. The covalent binding of drugs to tissue macromolecules has traditionally been associated with toxicity. Further research is required to elucidate the role of acyl-glucuronide conjugates in the formation of drug-protein adducts and their biological consequences.
Assuntos
Proteínas Sanguíneas/metabolismo , Ácido Clofíbrico/farmacocinética , Fígado/metabolismo , Proteínas/metabolismo , Animais , Ácido Clofíbrico/sangue , Ácido Clofíbrico/uso terapêutico , Creatinina/sangue , Glucuronatos/metabolismo , Glucuronatos/urina , Humanos , Hipercolesterolemia/tratamento farmacológico , Masculino , Ratos , Análise de RegressãoRESUMO
The in vitro binding of the lipid lowering agent Ciprofibrat (1) to different plasma protein fractions and its red blood-cell partition coefficient were investigated. The binding-rate to albumin and alpha-globulin is dose-dependent (first order kinetic) and amounts to about 95% for albumin and to 25% for alpha-globulin. The affinity of 1 to beta- and gamma-globulin is non-specific and dose-independent (average binding-rate 8% and 10%, respectively). 1 shows only a weak affinity to erythrocytes, therefore, the red blood-cell partition coefficient is 0.02.
Assuntos
Ácido Clofíbrico/análogos & derivados , Hipolipemiantes/sangue , Proteínas Sanguíneas/metabolismo , Ácido Clofíbrico/sangue , Eritrócitos/metabolismo , Ácidos Fíbricos , Humanos , Técnicas In Vitro , Ligação ProteicaRESUMO
1. The kinetics of the hypolipidaemic drug, ciprofibrate, were studied after a single oral dose (100 mg) in subjects with normal renal function (n = 6), patients with mild (n = 6) and severe (n = 6) renal insufficiency as well as in haemodialysed patients (n = 5). 2. Under fasting conditions, ciprofibrate, was absorbed rapidly in subjects with normal renal function, and its apparent elimination half-life was approximately 81 h. Both renal clearance (0.15 ml min-1) and cumulative renal excretion (less than 7% of the administered dose) were low. 3. Mild renal insufficiency did not alter the pharmacokinetics of ciprofibrate, but severe renal impairment significantly reduced both its renal clearance and cumulative urinary excretion and increased the apparent elimination half-life. 4. A 5 h haemodialysis session did not lower the plasma concentrations of ciprofibrate. 5. It is concluded that, from a pharmacokinetic point of view, a reduction in the dosage of ciprofibrate should be considered in patients with a glomerular filtration rate below 30 ml min-1/1.73 m2.
Assuntos
Clofibrato/análogos & derivados , Ácido Clofíbrico/análogos & derivados , Hipolipemiantes/farmacocinética , Nefropatias/metabolismo , Diálise Renal , Adulto , Idoso , Ácido Clofíbrico/sangue , Ácido Clofíbrico/farmacocinética , Ácido Clofíbrico/urina , Feminino , Ácidos Fíbricos , Humanos , Hipolipemiantes/sangue , Hipolipemiantes/urina , Nefropatias/terapia , Masculino , Pessoa de Meia-IdadeRESUMO
As a basis for establishing dosing guidelines in order to avoid side effects due to overdosage, the concentrations of total and free non-protein bound clofibrinic acid (CA) were determined before and after the administration of a single clofibrate dose (0, 2, 6, 12, 24, 48, 72, 96h) in patients with various degrees of impaired renal function and in a control group (n = 56). The clofibrate doses administered to the five groups were: group 0 = control group without renal impairment: 1,000 mg; group 1 = serum creatinine up to 354 mumol/l: 1,000 mg; group 2a = creatinine levels greater than 354 mumol/l up to levels requiring dialysis: 1,000 mg; group 2b = creatinine levels like 2a, but only 500 mg; group 3 = patients requiring dialysis: 500 mg. In addition, serum albumin, CK, GOT and GPT were controlled. Total CA was determined by gas chromatography, the unbound fraction by equilibrium dialysis. Increasing serum creatinine levels were correlated with a decrease of total CA but with a statistically significant increase in free CA concentrations. The levels of non-protein bound CA of groups 1 and 2a were significantly different from control group 0 (same dosing). In addition, a significantly negative correlation between free CA and serum albumin levels was demonstrated. Determination of free CA as a control parameter of clofibrate therapy in patients with impaired renal function allows clofibrate dosing to be closer related to the individual subject than the determination of total CA only.
Assuntos
Clofibrato/análogos & derivados , Ácido Clofíbrico/sangue , Falência Renal Crônica/sangue , Adulto , Clofibrato/administração & dosagem , Ácido Clofíbrico/administração & dosagem , Creatinina/sangue , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Ligação Proteica , Albumina Sérica/análiseRESUMO
The clofibric acid levels in blood are studied after the oral administration of 500 mg of etofibrate given as a unique dose in three different delayed-release tablets. These are enteric-coated, obtained by granule compression. An inert matrix containing the drug is the basis of these granules, differentiated by their granulometry and the chemical treatment applied. One of the three tablets presents a very interesting KE, which permits the substitution of three intakes throughout the day by only one dose daily.
Assuntos
Clofibrato/análogos & derivados , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/sangue , Adulto , Biotransformação , Ácido Clofíbrico/administração & dosagem , Ácido Clofíbrico/metabolismo , Preparações de Ação Retardada , Feminino , Humanos , Cinética , Masculino , Comprimidos com Revestimento EntéricoRESUMO
The disposition of clofibric acid, a drug metabolised largely by glucuronidation, was studied in eight males, eight females and eight females receiving oral contraceptive steroids (OCS). Clofibric acid plasma clearance was not significantly different in males compared to the control female group but was 48% greater (P less than 0.01) in women receiving OCS compared to non-pill using females. This difference was due to an alteration in clofibric acid metabolic clearance as there were no differences between the groups in clofibric acid free fraction. Along with previous data the results suggest that induction of drug glucuronidation by OCS may be of clinical importance, although any sex-related differences are unlikely to be of clinical significance.
PIP: The disposition of clofibric acid, a drrug metabolized largely by glucuronidation, was studied in 8 males, 8 females, and 8 females receiving oral contraceptives (OCs). Clofibric acid plasma clearance was not significantly different in males compared with the control female group but was 48% greater (P less than 0.01) in women receiving OCs compared with nonpill-using females. This difference was due to an alteration in clofibric acid metabolic clearance because there were no differences between the groups in clofibric acid free fraction. Along with previous data, the results suggest that induction of drug glucuronidation by OCs may be of clinical importance, although any sex-related differences are unlikely to be of clinical significance.
Assuntos
Clofibrato/análogos & derivados , Ácido Clofíbrico/metabolismo , Anticoncepcionais Orais Hormonais/farmacologia , Anticoncepcionais Orais/farmacologia , Adulto , Ácido Clofíbrico/sangue , Feminino , Glucuronatos/metabolismo , Humanos , Cinética , Masculino , Taxa de Depuração Metabólica/efeitos dos fármacos , Fatores SexuaisRESUMO
Clofibric acid has been shown previously to undergo a futile cycle in which its net clearance is dependent upon conjugation to form an acyl (ester) glucuronide and a combination of hydrolysis of the conjugate and its renal clearance. If hydrolysis is mediated by esterases then inhibition of these enzymes should increase clofibric acid clearance. Plasma clofibric acid clearance was measured in a group of six rabbits both while conscious and then while anesthetized and treated with diisopropylfluorophosphate (DFP). Clofibric acid clearance also was determined in a control group of six rabbits both while conscious and subsequently while anesthetized. Plasma clearances of unbound and total clofibric acid (protein bound plus unbound) were similar in both groups while conscious but increased 2-fold in DFP-treated compared with conscious animals (P less than .001) and were 3-fold greater in DFP-treated animals than in control, anesthetized animals (P less than .001). These data support the futile cycle for clofibric and implicate esterases in the in vivo hydrolysis of clofibric acid glucuronide.
Assuntos
Clofibrato/análogos & derivados , Ácido Clofíbrico/sangue , Isoflurofato/farmacologia , Anestesia , Animais , Pressão Sanguínea/efeitos dos fármacos , Ácido Clofíbrico/análogos & derivados , Hidrólise , Masculino , Taxa de Depuração Metabólica , Modelos Biológicos , CoelhosRESUMO
A study was designed to investigate the effect of a fatty meal on the absorption of chlorophenoxyisobutyric acid (CPIB) in six healthy adult volunteers after oral administration of the p-chlorophenolic (PCP) ester of CPIB. Plasma concentrations of CPIB when administered with food were higher than those observed in the fasting state. The Cmax in the former case was 24.0 +/- 4.6 mg l-1 as against a value of 15.2 +/- 6.9 mg l-1 in the latter (P less than 0.01). The pharmacokinetic parameters measured were found to be linear with the dose administered. This could be due to low plasma concentrations of CPIB unable to cause a saturation of the plasma protein binding of this drug. It is concluded that a fatty meal enhances the absorption of this hypolipidaemic drug.